Diabetes Metab J.  2015 Feb;39(1):16-26. 10.4093/dmj.2015.39.1.16.

The Optimal Cutoff Value of Glycated Hemoglobin for Detection of Diabetic Retinopathy

• Kim JM
• Kim DJ

• KMID: 2280652
• DOI: http://doi.org/10.4093/dmj.2015.39.1.16

Abstract

With standardization of measurement of glycated hemoglobin (A1C), the International Expert Committee Report in 2009 and the American Diabetes Association in 2010 recommended incorporating A1C > or =6.5% into the previous diagnostic criteria using fasting plasma glucose and/or 2-hour plasma glucose. Whereas the association of A1C with cardiovascular diseases and other diabetic microvascular complications was linear without evidence of a distinct threshold, several studies suggested a threshold value for A1C in diabetic retinopathy (DR). In studies about the optimal cutoff value for A1C in DR, the A1C values range from 5.2% to 7.8%. There are several possible reasons why these values for DR differ so widely (differences in the definition and/or methods for DR, variation in statistical methods, differences in study population, differences in exclusion criteria, and difference in methods for measuring A1C). With these wide variations in the study method, drawing a conclusive cutoff value for A1C in DR is impossible. In published studies, the cutoff values for moderate or severe DR were higher than those for any or mild DR (6.4% to 7.0% vs. 5.5% to 6.5%).

Keyword

Diabetes mellitus; Diabetic retinopathy; Hemoglobin A, glycosylated

MeSH Terms

Blood Glucose
Cardiovascular Diseases
Diabetes Mellitus
Diabetic Retinopathy*
Fasting
Hemoglobin A, Glycosylated*
Hemoglobin A, Glycosylated

Reference

1. World Health Organization. WHO Expert Commitee on diabetes mellitus: second report: Technical Report Series 646. 1980. cited 2015 Jan 8. Available from: http://whqlibdoc.who.int/trs/WHO_TRS_646.pdf?ua=1.

2. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009; 32:1327–1334.

3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33:Suppl 1. S62–S69.

4. World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. cited 2015 Jan 8. Available from: http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/.

5. Santos-Oliveira R, Purdy C, da Silva MP, dos Anjos Carneiro-Leao AM, Machado M, Einarson TR. Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia. 2011; 54:1327–1334.

6. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, Sigurdsson G, Danesh J, Gudnason V. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010; 7:e1000278.

7. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999; 22:233–240.

8. Sabanayagam C, Liew G, Tai ES, Shankar A, Lim SC, Subramaniam T, Wong TY. Relationship between glycated haemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes? Diabetologia. 2009; 52:1279–1289.

9. Allen DW, Schroeder WA, Balog J. Observations on the chromatographic heterogeneity of normal adult and fetal human hemoglobin: a study of the effects of crystallization and chromatography on the heterogeneity and isoleucine content. J Am Chem Soc. 1958; 80:1628–1634.

10. Huisman TH, Meyering CA. Studies on the heterogeneity of hemoglobin. I. The heterogeneity of different human hemoglobin types in carboxymethylcellulose and in amberlite IRC-50 chromatography qualitative aspects. Clin Chim Acta. 1960; 5:103–123.

11. Huisman TH, Dozy AM. Studies on the heterogeneity of hemoglobin. V. Binding of hemoglobin with oxidized glutathione. J Lab Clin Med. 1962; 60:302–319.

12. Rahbar S. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968; 22:296–298.

13. Dolhofer R, Wieland OH. In vitro glycosylation of hemoglobins by different sugars and sugar phosphates. FEBS Lett. 1978; 85:86–90.

14. Koenig RJ, Blobstein SH, Cerami A. Structure of carbohydrate of hemoglobin AIc. J Biol Chem. 1977; 252:2992–2997.

15. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest. 1976; 57:1652–1659.

16. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med. 1976; 295:417–420.

17. Gabbay KH, Hasty K, Breslow JL, Ellison RC, Bunn HF, Gallop PM. Glycosylated hemoglobins and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab. 1977; 44:859–864.

18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977–986.

19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837–853.

20. John WG. Haemoglobin A1c: analysis and standardisation. Clin Chem Lab Med. 2003; 41:1199–1212.

21. NGSP. Harmonizing hemoglobin A1c testing. cited 2014 Oct 10. Available from: http://www.ngsp.org/.

22. Castagnola M, Caradonna P, Salvi ML, Rossetti D. Investigation of the heterogeneity of hemoglobin by cation-exchange chromatography on Bio-REX 70. J Chromatogr. 1983; 272:51–65.

23. Finke A, Kobold U, Hoelzel W, Weykamp C, Miedema K, Jeppsson JO. Preparation of a candidate primary reference material for the international standardisation of HbA1c determinations. Clin Chem Lab Med. 1998; 36:299–308.

24. Consensus Committee. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care. 2007; 30:2399–2400.

25. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ. 1994; 308:1323–1328.

26. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997; 20:785–791.

27. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997; 20:1183–1197.

28. Almdal TP, Handlos LN, Valerius M, Juul E, Nielsen KE, Vistisen D, Nielsen LB, Sheikh A, Belhadj M, Nadir D, Zinai S, Raposo J, Lund-Andersen H, Witte DR. Glycaemic threshold for diabetes-specific retinopathy among individuals from Saudi Arabia, Algeria and Portugal. Diabetes Res Clin Pract. 2014; 103:e44–e46.

29. Cheng YJ, Gregg EW, Geiss LS, Imperatore G, Williams DE, Zhang X, Albright AL, Cowie CC, Klein R, Saaddine JB. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: implications for diabetes diagnostic thresholds. Diabetes Care. 2009; 32:2027–2032.

30. Colagiuri S, Lee CM, Wong TY, Balkau B, Shaw JE, Borch-Johnsen K. DETECT-2 Collaboration Writing Group. Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care. 2011; 34:145–150.

31. Selvin E, Ning Y, Steffes MW, Bash LD, Klein R, Wong TY, Astor BC, Sharrett AR, Brancati FL, Coresh J. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes. 2011; 60:298–305.

32. Tapp RJ, Zimmet PZ, Harper CA, de Courten MP, McCarty DJ, Balkau B, Taylor HR, Welborn TA, Shaw JE. AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract. 2006; 73:315–321.

33. Tsugawa Y, Mukamal KJ, Davis RB, Taylor WC, Wee CC. Should the hemoglobin A1c diagnostic cutoff differ between blacks and whites? A cross-sectional study. Ann Intern Med. 2012; 157:153–159.

34. Cho NH, Kim TH, Woo SJ, Park KH, Lim S, Cho YM, Park KS, Jang HC, Choi SH. Optimal HbA1c cutoff for detecting diabetic retinopathy. Acta Diabetol. 2013; 50:837–842.

35. Ito C, Maeda R, Ishida S, Harada H, Inoue N, Sasaki H. Importance of OGTT for diagnosing diabetes mellitus based on prevalence and incidence of retinopathy. Diabetes Res Clin Pract. 2000; 49:181–186.

36. Miyazaki M, Kubo M, Kiyohara Y, Okubo K, Nakamura H, Fujisawa K, Hata Y, Tokunaga S, Iida M, Nose Y, Ishibashi T, Hisayama s. Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population: the Hisayama Study. Diabetologia. 2004; 47:1411–1415.

37. Mukai N, Yasuda M, Ninomiya T, Hata J, Hirakawa Y, Ikeda F, Fukuhara M, Hotta T, Koga M, Nakamura U, Kang D, Kitazono T, Kiyohara Y. Thresholds of various glycemic measures for diagnosing diabetes based on prevalence of retinopathy in community-dwelling Japanese subjects: the Hisayama Study. Cardiovasc Diabetol. 2014; 13:45.

38. Tsugawa Y, Takahashi O, Meigs JB, Davis RB, Imamura F, Fukui T, Taylor WC, Wee CC. New diabetes diagnostic threshold of hemoglobin A(1c) and the 3-year incidence of retinopathy. Diabetes. 2012; 61:3280–3284.

39. Xin Z, Yuan MX, Li HX, Hua L, Feng JP, Shi J, Zhu XR, Cao X, Yang JK. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. PLoS One. 2012; 7:e40610.

40. Massin P, Lange C, Tichet J, Vol S, Erginay A, Cailleau M, Eschwege E, Balkau B. DESIR (Data From an Epidemiological Study on the Insulin Resistance Syndrome) Study Group. Hemoglobin A1c and fasting plasma glucose levels as predictors of retinopathy at 10 years: the French DESIR study. Arch Ophthalmol. 2011; 129:188–195.

41. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Polak BC. Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. Arch Ophthalmol. 2003; 121:245–251.

42. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995; 38:437–444.

43. Diabetic retinopathy study. Report number 6. Design, methods, and baseline results. Report number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the diabetic retinopathy. Invest Ophthalmol Vis Sci. 1981; 21(1 Pt 2):1–226.

44. Park YM, Ko SH, Lee JM, Kim DJ, Kim DJ, Han K, Bower JK, Ahn YB. Committee of Clinical Practice Guideline, Korean Diabetes Association. Glycaemic and haemoglobin A1c thresholds for detecting diabetic retinopathy: the fifth Korea National Health and Nutrition Examination Survey (2011). Diabetes Res Clin Pract. 2014; 104:435–442.

45. Yu T, Mitchell P, Berry G, Li W, Wang JJ. Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol. 1998; 116:83–89.

46. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156:871–881.

47. Wong TY, Liew G, Tapp RJ, Schmidt MI, Wang JJ, Mitchell P, Klein R, Klein BE, Zimmet P, Shaw J. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. Lancet. 2008; 371:736–743.

48. Muller RA, Kleinhans N, Courchesne E. Linguistic theory and neuroimaging evidence: an fMRI study of Broca's area in lexical semantics. Neuropsychologia. 2003; 41:1199–1207.

49. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, Sullivan L, D'Agostino RB, Nathan DM. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care. 2008; 31:1991–1996.

50. Lee H, Oh JY, Sung YA, Kim DJ, Kim SH, Kim SG, Moon S, Park IeB, Rhee EJ, Chung CH, Kim BJ, Ku BJ. Optimal hemoglobin A1C cutoff value for diagnosing type 2 diabetes mellitus in Korean adults. Diabetes Res Clin Pract. 2013; 99:231–236.

51. Kramer CK, Araneta MR, Barrett-Connor E. A1C and diabetes diagnosis: the Rancho Bernardo Study. Diabetes Care. 2010; 33:101–103.

52. Kim JM, Hong JW, Won JC, Noh JH, Ko KS, Rhee BD, Kim DJ. Glycated hemoglobin value for fasting plasma glucose of 126 mg/dL in Korean: the 2011 Korea National Health and Nutrition Examination Survey. Diabetes Metab J. 2014; 38:480–483.

53. Kilpatrick ES, Dominiczak MH, Small M. The effects of ageing on glycation and the interpretation of glycaemic control in type 2 diabetes. QJM. 1996; 89:307–312.

54. Christensen DL, Witte DR, Kaduka L, Jorgensen ME, Borch-Johnsen K, Mohan V, Shaw JE, Tabak AG, Vistisen D. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care. 2010; 33:580–582.

55. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, Lachin JM, Montez MG, Brenneman T, Barrett-Connor E. Diabetes Prevention Program Research Group. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30:2453–2457.

56. Likhari T, Gama R. Glycaemia-independent ethnic differences in HbA(1c) in subjects with impaired glucose tolerance. Diabet Med. 2009; 26:1068–1069.

57. Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005; 51:776–778.

58. Mostafa SA, Davies MJ, Webb D, Gray LJ, Srinivasan BT, Jarvis J, Khunti K. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting type 2 diabetes mellitus. Diabet Med. 2010; 27:762–769.

59. John WG. UK Department of Health Advisory Committee on Diabetes. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. Diabet Med. 2012; 29:1350–1357.

60. El-Agouza I, Abu Shahla A, Sirdah M. The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. Clin Lab Haematol. 2002; 24:285–289.

61. Jaisson S, Pietrement C, Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem. 2011; 57:1499–1505.